Galmed Pharmaceuticals (GLMD) Cash from Investing Activities (2013 - 2026)

Galmed Pharmaceuticals' Cash from Investing Activities history runs 14 years deep, the most recent figure standing at $152000.0 for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 165.8% year-over-year to $152000.0; the TTM figure through Mar 2026 stood at $373000.0 (down 55.33% YoY), while the FY2025 annual figure was -$10000.0, down 100.67% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $152000.0, down from $4.8 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $6.3 million in Q1 2022, with the low at -$4.6 million in Q2 2025.
• The 5-year median for Cash from Investing Activities is $705000.0 (2023), against an average of $1.2 million.
• Peak annual rise in Cash from Investing Activities reached 609.89% in 2025, while the deepest fall reached 428.23% in 2025.
• Galmed Pharmaceuticals' Cash from Investing Activities stood at $2.0 million in 2022, then advanced by 15.16% to $2.3 million in 2023, then slumped by 141.25% to -$940000.0 in 2024, then surged by 609.89% to $4.8 million in 2025, then plunged by 96.83% to $152000.0 in 2026.
• Business Quant data shows GLMD's Cash from Investing Activities at $152000.0 in Q1 2026, $4.8 million in Q4 2025, and -$3000.0 in Q3 2025.